BACKGROUND: Cognitive decline has been reported in Huntington disease (HD), as well as in the period before diagnosis of motor symptoms (i.e., pre-HD). However, the severity, frequency, and characterization of cognitive difficulties have not been well-described. Applying similar cutoffs to those used in mild cognitive impairment (MCI) research, the current study examined the rates of subtle cognitive dysfunction (e.g., dysfunction that does not meet criteria for dementia) in pre-HD. METHODS: Using baseline data from 160 non-gene-expanded comparison participants, normative data were established for cognitive tests of episodic memory, processing speed, executive functioning, and visuospatial perception. Cutoff scores at 1.5 standard deviations below the mean of the comparison group were then applied to 575 gene-expanded pre-HD participants from the observational study, PREDICT-HD, who were stratified by motor signs and genetic risk for HD. RESULTS: Nearly 40% of pre-HD individuals met criteria for MCI, and individuals closer to HD diagnosis had higher rates of MCI. Nonamnestic MCI was more common than amnestic MCI. Single-domain MCI was more common than multiple-domain MCI. Within the nonamnestic single-domain subtype, impairments in processing speed were most frequent. CONCLUSIONS: Consistent with the Alzheimer disease literature, MCI as a prodromal period is a valid concept in pre-HD, with nearly 40% of individuals showing this level of impairment before diagnosis. Future studies should examine the utility of MCI as a marker of cognitive decline in pre-HD.
BACKGROUND:Cognitive decline has been reported in Huntington disease (HD), as well as in the period before diagnosis of motor symptoms (i.e., pre-HD). However, the severity, frequency, and characterization of cognitive difficulties have not been well-described. Applying similar cutoffs to those used in mild cognitive impairment (MCI) research, the current study examined the rates of subtle cognitive dysfunction (e.g., dysfunction that does not meet criteria for dementia) in pre-HD. METHODS: Using baseline data from 160 non-gene-expanded comparison participants, normative data were established for cognitive tests of episodic memory, processing speed, executive functioning, and visuospatial perception. Cutoff scores at 1.5 standard deviations below the mean of the comparison group were then applied to 575 gene-expanded pre-HDparticipants from the observational study, PREDICT-HD, who were stratified by motor signs and genetic risk for HD. RESULTS: Nearly 40% of pre-HD individuals met criteria for MCI, and individuals closer to HD diagnosis had higher rates of MCI. Nonamnestic MCI was more common than amnestic MCI. Single-domain MCI was more common than multiple-domain MCI. Within the nonamnestic single-domain subtype, impairments in processing speed were most frequent. CONCLUSIONS: Consistent with the Alzheimer disease literature, MCI as a prodromal period is a valid concept in pre-HD, with nearly 40% of individuals showing this level of impairment before diagnosis. Future studies should examine the utility of MCI as a marker of cognitive decline in pre-HD.
Authors: Alonso Montoya; Marc Pelletier; Matthew Menear; Elisabeth Duplessis; François Richer; Martin Lepage Journal: Neuropsychologia Date: 2006-06-23 Impact factor: 3.139
Authors: Karin F Hoth; Jane S Paulsen; David J Moser; Daniel Tranel; Lee Anna Clark; Antoine Bechara Journal: J Clin Exp Neuropsychol Date: 2007-05 Impact factor: 2.475
Authors: Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Julie C Stout Journal: Biol Psychiatry Date: 2007-05-03 Impact factor: 13.382
Authors: Vladimir Hachinski; Costantino Iadecola; Ron C Petersen; Monique M Breteler; David L Nyenhuis; Sandra E Black; William J Powers; Charles DeCarli; Jose G Merino; Raj N Kalaria; Harry V Vinters; David M Holtzman; Gary A Rosenberg; Anders Wallin; Martin Dichgans; John R Marler; Gabrielle G Leblanc Journal: Stroke Date: 2006-08-17 Impact factor: 7.914
Authors: Eric A Epping; Ji-In Kim; David Craufurd; Thomas M Brashers-Krug; Karen E Anderson; Elizabeth McCusker; Jolene Luther; Jeffrey D Long; Jane S Paulsen Journal: Am J Psychiatry Date: 2015-10-16 Impact factor: 18.112
Authors: Jane S Paulsen; Jeffrey D Long; Christopher A Ross; Deborah L Harrington; Cheryl J Erwin; Janet K Williams; Holly James Westervelt; Hans J Johnson; Elizabeth H Aylward; Ying Zhang; H Jeremy Bockholt; Roger A Barker Journal: Lancet Neurol Date: 2014-11-03 Impact factor: 44.182
Authors: Elizabeth H Aylward; Deborah L Harrington; James A Mills; Peggy C Nopoulos; Christopher A Ross; Jeffrey D Long; Dawei Liu; Holly K Westervelt; Jane S Paulsen Journal: J Huntingtons Dis Date: 2013
Authors: Julia A Rao; Deborah L Harrington; Sally Durgerian; Christine Reece; Lyla Mourany; Katherine Koenig; Mark J Lowe; Vincent A Magnotta; Jeffrey D Long; Hans J Johnson; Jane S Paulsen; Stephen M Rao Journal: Cortex Date: 2014-06-02 Impact factor: 4.027
Authors: Julie C Stout; Jane S Paulsen; Sarah Queller; Andrea C Solomon; Kathryn B Whitlock; J Colin Campbell; Noelle Carlozzi; Kevin Duff; Leigh J Beglinger; Douglas R Langbehn; Shannon A Johnson; Kevin M Biglan; Elizabeth H Aylward Journal: Neuropsychology Date: 2011-01 Impact factor: 3.295
Authors: N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella Journal: Qual Life Res Date: 2016-08-13 Impact factor: 4.147